Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma. Currently in Phase II clinical development, CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified to target multiple myeloma. Arcellx will receive an […]
